Scientific Programme

Wednesday, 06 June 2018

Meetings and Courses
09:00 - 17:00 Room 15

An introductory course in cognitive behavioural therapy and interpersonal therapy**

**** Extra registration required**

Alexandra Klein Rafaeli

CBT principles: assessment and formulation, session structure, cognitive restructuring, exposure experiments, transdiagnostic treatment goals, monitoring and homework

The third wave of CBT: introduction to mindfulness

Coffee Break

What is IPT and how is it similar to/different from CBT?

Lunchbreak

How to conduct the interpersonal inventory

Coffee Break

IPT Case Formulation: identifying interpersonal problem areas IPT Techniques: communication analysis and roleplaying. Termination Phase and Conclusion (CBT and IPT)

Meetings and Courses
10:00 - 12:20 Amphitheatre

The treatment of adults with CF - an in-depth course

Wednesday 6 June - All day

In many countries, there are now more adults than children with CF. Therefore, this course is specifically designed for pulmonologists and invites them to deepen their knowledge on the treatment of adults with CF.

Carsten Schwarz (Berlin, Germany)

Introduction and adult CF epidemiology
Pierre-Régis Burgel (Paris, France)

Gram-negative infections and their treatment
Lieven Dupont (Leuven, Belgium)

'Other' pathogens and their treatment
Carsten Schwarz (Berlin, Germany)

Pulmonary complications and their treatment
Nicholas Simmonds (London, United Kingdom)

Scientific Programme

Meetings and Courses
13:30 - 16:40 Amphitheatre

The treatment of adults with CF - an in-depth course

Wednesday 6 June - All day

In many countries, there are now more adults than children with CF. Therefore, this course is specifically designed for pulmonologists and invites them to deepen their knowledge on the treatment of adults with CF.

Stuart Elborn (London, United Kingdom)

Comorbidities in adults with CF
Amparo Solé (Valencia, Spain)

Standards of Care / Segregation / Hygiene / Multidisciplinary teams / Quality control
Daniel Peckham (Leeds, United Kingdom)

Coffee Break

Pipeline of treatments correcting the basic CF defect
Stuart Elborn (London, United Kingdom)

Discussion on the need for and challenges of adult CF clinics in the Balkans
Predrag Minic (Belgrade, Serbia)

Closing remarks

14:30 - 17:00 Room 4

Physiotherapy Case Presentations

Opening Plenary
18:30 - 20:00 Blue Hall

Opening Plenary

Clinical trials from an ethical perspective **18:30 - 18:50**
Suzanne van de Vathorst (Rotterdam, Netherlands)

Welcome Reception
20:00 - 21:30 Hall 2

Welcome Reception

Scientific Programme

Thursday, 07 June 2018

Satellite Symposium
07:15 - 08:15 Amphitheatre

Satellite Symposium

Please find the detailed program of the Satellite Symposia here.

Symposium
08:30 - 10:00 Blue Hall

S01, Microbiome directed treatment

Upon completion of this session participants should be able to:
- Have an overview of the lung and gut microbiome in CF
- Understand the impact of antibiotic treatment on the lung and gut microbiome
- Learn if microbiome directed antibiotic therapy is more effective than conventional microbiology in treating pulmonary exacerbations in CF

Michael Tunney (Belfast, United Kingdom)
Barry Plant (Cork, Ireland)

The CF microbiome – where are we now? **08:30 - 08:52**
Debby Bogaert (Edinburgh, United Kingdom)

Microbiome directed antibiotic treatment of pulmonary exacerbations – results of an international randomised controlled trial **08:52 - 09:14**
Barry Plant (Cork, Ireland)

The lung/gut axis – longitudinal microbiome **09:14 - 09:36**
Gisli Einarsson (Belfast, United Kingdom)

Immune response in a mouse model of chronic infection **09:36 - 10:00**
Pierre-Régis Burgel (Paris, France)

Symposium
08:30 - 10:00 Hall 1

S02, CF centre care of the future

Upon completion of this session participants should be able to:
- Learn how to reduce the risk of cross infection in CF centres of the future
- Understand how new technologies will enable better monitoring of patients and potentially earlier intervention
- Understand how trans-border networks could enhance clinical care

Andres Floto (Cambridge, United Kingdom)
Hannah Blau (Petah Tikva, Israel)

Optimising new CF centre design from an infection, prevention and control perspective **08:30 - 08:52**
Lisa Saiman (New York, United States)

Scientific Programme

How remote monitoring and biosensor technologies may change CF management? **08:52 - 09:14**
Jane Davies (London, United Kingdom)

Use of machine learning to predict pulmonary exacerbations **09:14 - 09:36**
Andres Floto (Cambridge, United Kingdom)

Trans-border advice: its place in CF care and the role of the European Reference Network to implement it **09:36 - 10:00**
Kors Van der Ent (Utrecht, Netherlands)

Symposium
08:30 - 10:00 Amphitheatre

S03, Instructions for a wise use of CF genetics

The objectives of the session are to:
- Summarise current knowledge on the interactions between the genotype and phenotype
- Explain the new terminology of theratypes
- Appraise home genetic testing for CF

Dragica Radojković (Belgrade, Serbia)
Milan Jr Macek (Prague, Czech Republic)

European quality control for CFTR genetic analysis – the results **08:30 - 08:52**
Els Dequeker (Leuven, Belgium)

Direct to consumer genetic tests: what is their safety and efficacy? How to interpret their results? **08:52 - 09:14**
Milan Jr Macek (Prague, Czech Republic)

Theratypes: what are they? How can they help treating patients? **09:14 - 09:36**
Margarida Amaral (Lisbon, Portugal)

Update on CF modifier genes **09:36 - 10:00**
Harriet Corvol (Paris, France)

Symposium
08:30 - 10:00 Hall 2

S04, Start of life to end of life: living with uncertainty

Upon completion of this session participants should be able to:
- Summarise the complexities associated with newborn screening in CF and consider how these are communicated to carers and colleagues
- Consider how teams can prepare for the changing needs of patients with CF in the 21st century
- Discuss how CFTR-RD is managed in adult services and critically reflect on learning from these cases to help guide the care of CFSPID-CRMD

Anne Munck (Paris, France)
Urszula Borawska - Kowalczyk (Warsaw, Poland)

Start of life discussions - what do these genes mean? - communication complexity **08:30 - 08:52**
Colin Wallis (London, United Kingdom)

Scientific Programme

Changing (un)certainties in CF and the challenges for MD teams **08:52 - 09:14**
Susan Madge (London, United Kingdom)

CFTR-RD: is this adult CFSPID? **09:14 - 09:36**
Carlo Castellani (Verona, Italy)

Uncertainty for the MDT: how is CFTR-RD managed? **09:36 - 10:00**
Isabelle Durieu (Lyon, France)

Symposium
08:30 - 10:00 Annex A

S05, Evolving the role of physiotherapy

Marta Kerstan (Biberstein, Switzerland)
Ruth Dentice (Sydney, Australia)

Arthropathy and arthritis **08:30 - 08:52**
Elizabeth Clarke (Manchester, United Kingdom)

Coaching for success, the upper airway **08:52 - 09:14**
William Poncin (Brussels, Belgium)

Incontinence **09:14 - 09:36**
Sophie Ramel (Roscoff, France)

How to treat pain? **09:36 - 10:00**
Dominique Hubert (Paris, France)

Symposium
08:30 - 10:00 Annex B

S06, What’s going on below the diaphragm?

Upon completion of this session participants should be able to:
- Better understand the impact of nutrition on the gut microbiome
- Learn that pancreatitis is more than pancreatitis
- Learn the impact of endocrine dysfunction of the pancreas on disease progression
- Learn the importance of recognising the micronutrient deficiency in CF

Stephanie Van Biervliet (Ghent, Belgium)
Duška Drinković-Tješić (Zagreb, Croatia)

The influence of diet on gut microbiome **08:30 - 08:52**
Daniel Peckham (Leeds, United Kingdom)

Two questions on pancreatitis: when is it worth thinking of cystic fibrosis / can new therapies increase the incidence? **08:52 - 09:14**
Michael Wilschanski (Jerusalem, Israel)

Pancreatic endocrine dysfunction in cystic fibrosis **09:14 - 09:36**
Antoinette M. Moran (Minneapolis, United States)

Scientific Programme

Recognising trace elements and vitamin deficiencies **09:36 - 10:00**
Konstantinos Gerasimidis (Glasgow, United Kingdom)

Satellite Symposium
10:00 - 10:30 ePoster Corners

Satellite Workshop

ePoster Corner A
Please find the detailed program of this session here.

Symposium
10:30 - 12:00 Blue Hall

S07, Mix and match! Combination CFTR modulation therapies and new trials

Upon completion of this session participants should be able to:
- Describe approaches of CFTR modulation in different drug development programs
- Evaluate how different correctors and potentiators may impact CFTR function
- Assess effectiveness and side effects of new correctors and potentiators

Pavel Drevinek (Prague, Czech Republic)
Silke van Koningsbruggen-Rietschel (Cologne, Germany)

Galapagos : new study results/development pipeline **10:30 - 10:52**
Katja Conrath (Mechelen, Belgium)

Flatley : new study results/development pipeline **10:52 - 11:14**
Claudia Ordonez (Charlestown, United States)

Proteostasis : new study results/development pipeline **11:14 - 11:36**
Geoffrey Gilmartin (Cambridge, United States)

Vertex : new study results/development pipeline **11:36 - 12:00**
Charlotte McKee (Boston, United States)

Symposium
10:30 - 12:00 Hall 1

S08, How do pathogens become multiresistant?

Upon completion of this session participants should be able to:
- Classify the key mechanisms of bacterial resistance to antibiotics and how pathogens develop or acquire resistance
- Identify antibiotic resistance rates of CF pathogens and their clinical implications
- Discuss how choosing antibiotics based on biofilm rather than conventional antimicrobial susceptibility testing could influence treatment response

Barbara Kahl (Münster, Germany)
Eshwar Mahenthiralingam (Cardiff, United Kingdom)

Efflux pumps and resistance mechanisms in CF pathogens **10:30 - 10:52**
Silvia Buroni (Pavia, Italy)

Scientific Programme

Mechanisms of resistance and susceptibility in CF pathogens **10:52 - 11:14**
Francoise van Bambeke (Brussels, Belgium)

Evolution of resistance **11:14 - 11:36**
Carla Lopez Causapé (Palma de Mallorca, Spain)

Biofilm resistance and testing **11:36 - 12:00**
Claus Moser (Copenhagen, Denmark)

Symposium
10:30 - 12:00 Amphitheatre

S09, NTM: sources, transmission and treatments

Upon completion of this session participants should be able to:
- Understand the evidence supporting Pseudomonas eradication regimens
- Learn about the natural history and treatment approaches to other difficult Gram-negative organisms
- Understand the evidence supporting MRSA eradication regimens

Charles Haworth (Cambridge, United Kingdom)
Rachel Thomson (Brisbane, Australia)

Environmental sources of NTM infection **10:30 - 10:52**
Rachel Thomson (Brisbane, Australia)

Patient-to-patient transmission: whole genome sequencing update **10:52 - 11:14**
Marianne Skov (Copenhagen, Denmark)

M. abscessus treatment outcomes in cystic fibrosis **11:14 - 11:36**
Charles Haworth (Cambridge, United Kingdom)

Future therapies for NTM lung disease **11:36 - 12:00**
Andres Floto (Cambridge, United Kingdom)

Symposium
10:30 - 12:00 Hall 2

S10, Best of Journal of Cystic Fibrosis and Lancet Respiratory Medicine

This session will provide a forum for attendees to interact with the authors and editors of papers published in the journals. Papers presented will be recent publications, selected by the editors, and attendees will have the opportunity to hear presentations directly from the authors and editors, and address questions to both the authors and editors. The discussion is intended to provide insights into these papers, the selection process, and how the research applies directly to the field of CF.

Scott Bell (Brisbane, Australia)
Emma Grainger (London, United Kingdom)

Welcome **10:30 - 10:39**
Scott Bell (Brisbane, Australia)

Scientific Programme

Journal of Cystic Fibrosis One-time quantitative PCR detection of Pseudomonas aeruginosa to discriminate intermittent from chronic infection in cystic fibrosis **10:39 - 10:57**
Alexander Dalpke (Heidelberg, Germany)
Neils Hoiby (Denmark)

The Lancet Respiratory Medicine Article 01 **10:57 - 11:15**

Journal of Cystic Fibrosis Comparison of ex vivo and in vitro intestinal CF models to measure CFTR-dependant ion channel transport **11:15 - 11:33**
Jeffrey Beekman (Utrecht, Netherlands)
Nicholas Simmonds (London, United Kingdom)

The Lancet Respiratory Medicine Article 02 **11:33 - 11:51**

Conclusions **11:51 - 12:00**
Emma Grainger (London, United Kingdom)

Symposium
10:30 - 12:00 Annex A

S11, Fertility and reproductive challenges in cystic fibrosis

Upon completion of this session participants should be able to:
- Understand the importance of preconception counselling regarding parental genetics and longevity, appropriate medication use during pregnancy, and diabetes surveillance and control
- Learn about the management of male infertility
- Appreciate the complexities of pulmonary and extra-pulmonary management during pregnancy including antibiotic strategies, airway clearance strategies, the management of haemoptysis, ventilatory failure, nutrition, diabetes, and liver disease

Malena Cohen-Cymberknoh (Jerusalem, Israel)
Susan Madge (London, United Kingdom)

Preconception planning **10:30 - 10:52**
Hannah Blau (Petah Tikva, Israel)

Management of male infertility **10:52 - 11:14**
Susan Madge (London, United Kingdom)

Pulmonary management during pregnancy **11:14 - 11:36**
Malena Cohen-Cymberknoh (Jerusalem, Israel)

Management of extrapulmonary complications during pregnancy **11:36 - 12:00**
Jennifer Taylor-Cousar (Denver, United States)

Scientific Programme

Symposium
10:30 - 12:00 Annex B

S12, CFTR from structure to regulation

Upon completion of this session participants should be able to:
- Describe our present knowledge of the tridimensional structure of CFTR protein
- Discuss the importance of molecular interactions of CFTR with other proteins
- Appraise the potential use of novel structural information for the development of improved pharmacological modulators of mutant CFTR

Isabelle Callebaut (Paris, France)
Bertrand Kleizen (Utrecht, Netherlands)

CFTR 3-D structure and interaction with therapeutic drugs **10:30 - 10:52**
Bob Ford (Manchester, United Kingdom)

Effect of modulators on cooperative folding **10:52 - 11:14**
Bertrand Kleizen (Utrecht, Netherlands)

Molecular interactions at the plasma membrane to increase CFTR function **11:14 - 11:36**
Anjaparavanda P. Naren (Cincinnati, United States)

Identification of new active compounds using improved cellular assays **11:36 - 12:00**
Paola Vergani (London, United Kingdom)

Satellite Symposium
12:30 - 14:00 Blue Hall

Satellite Symposium

Please find the detailed program of the Satellite Symposia here.

Meet the Experts
12:45 - 13:45 ePoster Corners

Meet the Experts 1: Multidisciplinary team function and dysfunction

ePoster Corner A

Trudy Havermans (Leuven, Belgium)
Susan Madge (London, United Kingdom)

Scientific Programme

Meet the Experts
12:45 - 13:45 ePoster Corners

Meet the Expert 2: Match the drug to the bug

ePoster Corner B

Helle Krogh Johansen (Copenhagen, Denmark)
Giovanni Taccetti (Florence, Italy)

Meet the Experts
12:45 - 13:45 ePoster Corners

Meet the Expert 3: Feeding behaviour in cystic fibrosis

ePoster Corner C

Mandy Bryon (London, United Kingdom)
Jacqueline Lowdon (Leeds, United Kingdom)

Meetings and Courses
12:45 - 13:45 ECFS Tomorrow Lounge

Tomorrow Lounge Activity

ePoster Session
14:00 - 15:00 ePoster Corners

ePS3, New treatments: from genes to protein

ePoster Corner C

Marcus Mall (Berlin, Germany)
Jane Davies (London, United Kingdom)

Introduction **14:00 - 14:04**

Transduction of rhesus macaque lung following repeat dosing by adeno-associated virus serotype 1 **14:04 - 14:12**
Liudmila Cebotaru (Baltimore, United States)

Exploratory immune assays distinguish healthy volunteer from cystic fibrosis patient cohorts and were validated in a dose escalation study of QR-010 in subjects with cystic fibrosis homozygous for the F508del CFTR mutation **14:12 - 14:20**
Miriam Bujny (Leiden, Netherlands)

Effects of lumacaftor-ivacaftor therapy on CFTR function in Phe508del homozygous patients with cystic fibrosis **14:20 - 14:28**
Simon Graeber (Heidelberg, Germany)

Scientific Programme

Impact of CFTR modulation with ivacaftor on gut microbiota and intestinal inflammation **14:28 - 14:36**
Chee Y. Ooi (Randwick, Australia)

GLPG2222 in subjects with cystic fibrosis homozygous for F508del: results from a phase II study (FLAMINGO) **14:36 - 14:44**
Kors Van der Ent (Utrecht, Netherlands)

Safety, pharmacokinetics and pharmacodynamics of the CFTR corrector FDL169 **14:44 - 14:52**
Alexander Horsley (Manchester, United Kingdom)

Safety, tolerability and pharmacokinetics of the CFTR potentiator FDL176 **14:52 - 15:00**
Claudia Ordonez (Charlestown, United States)

ePoster Session
14:00 - 15:00 ePoster Corners

ePS2, Genotype/phenotype correlations: CFTR and other disease modifiers

ePoster Corner B

Harriet Corvol (Paris, France)
Michael Wilschanski (Jerusalem, Israel)

Introduction **14:00 - 14:04**

Association of polymorphic variants of GSTT1, GSTM1, GSTP1 and GCLC genes with the severity of the cystic fibrosis clinical manifestations **14:04 - 14:11**
Olga G. Novoselova (Moscow, Russian Federation)

Influence of phase 1 xenobiotics metabolism genes on the efficiency of antibacterial therapy in patients from the Russian Federation and the Republic of Belarus **14:11 - 14:18**
Elena Kondratyeva (Moscow, Russian Federation)

The influence of polymorphism of metalloproteinase genes on the formation of cystic fibrosis-liver cirrhosis and cystic fibrosis pneumofibrosis **14:18 - 14:25**
Anastasia Goryainova (Moscow, Russian Federation)

Combination of liver cirrhosis with mild mutation p.E92K **14:25 - 14:32**
Yulia Gorinova (Moscow, Russian Federation)

Genotype/phenotype correlation in cystic fibrosis children with mutation 3272-16T>A **14:32 - 14:39**
Vera Shadrina (Perm, Russian Federation)

Phenotypic manifestations of rare missense mutations **14:39 - 14:46**
Yulia Gorinova (Moscow, Russian Federation)

Intestinal current and nasal potential difference index cases: diagnostic features of subjects with CFTR-related disorder **14:46 - 14:53**
Burkhard Tümmler (Hanover, Germany)

Scientific Programme

Clinical characteristics of patients with one known cystic fibrosis-related mutation despite extended genotype testing **14:53 - 15:00**
Christopher Brockelsby (Liverpool, United Kingdom)

ePoster Session
14:00 - 15:00 ePoster Corners

ePS1, Airway epithelial cells to study cystic fibrosis pathogenesis and find new therapies

ePoster Corner A

Tanja Gonska (Toronto, Canada)
Nicoletta Pedemonte (Genoa, Italy)

Chronic rhinosinusitis: reduced Ca2+-mediated Cl- secretion observed in vitro is confirmed by nasal potential difference measurements in patients **14:00 - 14:10**
Johanna Salomon (Heidelberg, Germany)

Biochemical and biophysical properties of bronchial mucus from preschool children with cystic fibrosis **14:10 - 14:20**
Kathryn Ramsey (Bern, Switzerland)

Human respiratory epithelial cells prevent Aspergillus fumigatus germination **14:20 - 14:30**
Nicolas Richard (Paris, France)

Use of ex vivo paediatric primary nasal epithelial cultures to investigate TMEM16A as a potential therapeutic target in children with cystic fibrosis **14:30 - 14:40**
Iram Haq (Newcastle upon Tyne, United Kingdom)

CAT-5571 restores autophagy, a fundamental defect in cystic fibrosis, and is a potential new treatment for people with cystic fibrosis **14:40 - 14:50**
Feng Liu (Cambridge, United States)

Overproduction of IL-6 and TNF through IRE1α is CFTR genotype dependent **14:50 - 15:00**
Samuel Lara Reyna (Leeds, United Kingdom)

Meetings and Courses
14:00 - 15:00 ECFS Tomorrow Lounge

ECFS Tomorrow Lounge Activity

Scientific Programme

Workshop
15:00 - 16:30 Blue Hall

WS01, Exciting news from CFTR modulator clinical trials

Clinical Trials / New Therapies

Silke van Koningsbruggen-Rietschel (Cologne, Germany)
Lieven Dupont (Leuven, Belgium)

A phase 3, 2-part, single-arm study of ivacaftor treatment in patients < 2 years with a CFTR gating mutation: results from the ARRIVAL study in patients 1 to 2 years **15:00 - 15:15**
Margaret Rosenfeld (Seattle, United States)

Phase 2 initial results evaluating PTI-428, a novel CFTR amplifier, in patients with cystic fibrosis **15:15 - 15:30**
Patrick Flume (Charleston, United States)

Translational read-through of CFTR nonsense mutations and inducement of cystic fibrosis transmembrane conductance regulator (CFTR) function by ELX-02 treatment **15:30 - 15:45**
Neal Sharpe (Waltham, United States)

GLPG2222 in subjects with cystic fibrosis and the F508del/Class III mutation on stable treatment with ivacaftor: results from a phase II study (ALBATROSS) **15:45 - 16:00**
Scott Bell (Brisbane, Australia)

A 2-part, phase 3, single-arm study to evaluate the safety and pharmacokinetics (PK) of lumacaftor/ivacaftor (LUM/IVA) combination therapy in patients (pts) aged 2 to 5 years with cystic fibrosis homozygous for the F508del-CFTR mutation **16:00 - 16:15**
Gregory Sawicki (Boston, United States)

Preliminary safety and efficacy of triple combination CFTR modulator regimens in cystic fibrosis **16:15 - 16:30**
Jane Davies (London, United Kingdom)

Workshop
15:00 - 16:30 Hall 1

WS02, NTM: what's in the clinic, new diagnostics and treatments

Microbiology / Antibiotics

Andres Floto (Cambridge, United Kingdom)
Marianne Skov (Copenhagen, Denmark)

Epidemiology of nontuberculous mycobacteria infection in children and young people with cystic fibrosis: analysis of United Kingdom Cystic Fibrosis Trust Registry data **15:00 - 15:15**
Malcolm Brodlie (Newcastle upon Tyne, United Kingdom)

Prevalence of nontuberculous mycobacteria in potable water **15:15 - 15:30**
Rebecca Stockwell (Brisbane, Australia)

Scientific Programme

Antibody testing for Mycobacterium avium complex infection in cystic fibrosis patients **15:30 - 15:45**
Cecilie Ravnholt (Copenhagen, Denmark)

Glycopeptidolipids of the Mycobacterium abscessus cell wall are immunodominant antigens and represent potential targets for a diagnostic assay **15:45 - 16:00**
Carsten Schwarz (Berlin, Germany)

Treatment success for eradication of pulmonary nontuberculous mycobacterial infections in a paediatric cystic fibrosis cohort **16:00 - 16:15**
Dominic Hughes (London, United Kingdom)

Improving antibiotic activity against Mycobacterium abscessus isolates by inducing bacterial disaggregation and oxygen availability **16:15 - 16:30**
Mette Kolpen (Copenhagen, Denmark)

Interactive Poster Discussions
15:00 - 16:30 Amphitheatre

IPD1, Mental health in cystic fibrosis: assessment and care

Nursing / Psychosocial Issues

Mandy Bryon (London, United Kingdom)
Urszula Borawska - Kowalczyk (Warsaw, Poland)

Mental health screening in cystic fibrosis centres across Europe
Janice Abbott (Preston, United Kingdom)

Assessing strengths and difficulties as part of annual mental health screening
Alistair Duff (Leeds, United Kingdom)

Depression among parents of children with cystic fibrosis and its socioeconomic determinants
Renata Zubrzycka (Lublin, Poland)

Implementing the International Committee on Mental Health in Cystic Fibrosis (ICMH) guidelines: practical complexities of managing mental health
Marieke Verkleij (Amsterdam, Netherlands)

Instituting mental health screening in a Canadian paediatric cystic fibrosis clinic
Anna Gravelle (Vancouver, BC, Canada)

Outcome of mental screening among Swedish adolescents with cystic fibrosis
Carolina Laine (Stockholm, Sweden)

Cystic fibrosis: does the deterioration of pulmonary function affect the level of anxiety and depression?
Ivana Lalic (Zagreb, Croatia)

Treating unresolved grief in parents of children with cystic fibrosis
André Schultz (Perth, Australia)

Scientific Programme

Workshop
15:00 - 16:30 Hall 2

WS03, Towards optimal nutritional status

Open

Anne Munck (Paris, France)
Jochen G. Mainz (Jena, Germany)

Growth, body composition and lung function in pre-pubertal children with cystic fibrosis diagnosed via newborn screening, and comparison with a historical unscreened cohort **15:00 - 15:15**
Elizabeth Owen (London, United Kingdom)

The effect of an intensive residential rehabilitation program with adjusted nutritional care on body composition in adult patients with cystic fibrosis **15:15 - 15:30**
Sarah Buts (Ghent, Belgium)

Childhood nutritional status is a major factor determining lung function in adults with cystic fibrosis **15:30 - 15:45**
Moshe Ashkenazi (Ramat Gan, Israel)

Comparing abdominal symptoms in cystic fibrosis patients and healthy controls with a novel multimodal questionnaire (CF-Abd Score) **15:45 - 16:00**
Anke Jaudszus (Jena, Germany)

The human intestinal proteome in children with cystic fibrosis **16:00 - 16:15**
Michael Coffey (Sydney, Australia)

A first approach for an evidence-based method to adjust PERT: in vivo validation of the in vitro model **16:15 - 16:30**
Joaquim Calvo-Lerma (Valencia, Spain)

Workshop
15:00 - 16:30 Annex A

WS04, New ways to modulate inflammation in cystic fibrosis

Immunology / Pulmonology / Inflammation

Pierre-Régis Burgel (Paris, France)
Thomas Scambler (Leeds, United Kingdom)

Targeting IL-17-producing T-cells attenuates the severity of Pseudomonas aeruginosa lung infection **15:00 - 15:15**
Cristina Cigana (Milan, Italy)

Azithromycin treatment of Pseudomonas aeruginosa infection potentiates IgY pulmonary protection in vivo **15:15 - 15:30**
Kim Thomsen (Copenhagen, Denmark)

Sodium influx modulates innate immune inflammation and metabolism in cystic fibrosis **15:30 - 15:45**
Thomas Scambler (Leeds, United Kingdom)

Scientific Programme

Investigation of the CFTR-TGFβ1 interaction regarding inflammatory effects in wildtype and CFTR-mutated human bronchial epithelial cells **15:45 - 16:00**
Jan Christoph Thomassen (Cologne, Germany)

The effect of cysteamine and epigallocatechin gallate on hyperresponsive inflammation in cystic fibrosis **16:00 - 16:15**
Jonathan Holbrook (Leeds, United Kingdom)

Balancing the immune response in cystic fibrosis: using zebrafish models of inflammation to uncover new therapeutic approaches **16:15 - 16:30**
Audrey Bernut (Sheffield, United Kingdom)

Workshop
15:00 - 16:30 Annex B

WS05, Which factors influence outcomes from newborn to adulthood?

Epidemiology / Registry

Siobhan Carr (London, United Kingdom)
Christian Benden (Zurich, Switzerland)

Impact of newborn screening on outcomes and social inequalities in cystic fibrosis: a UK Registry-based study **15:00 - 15:15**
Daniela K. Schlüter (Lancaster, United Kingdom)

Impact of tobacco smoke exposure on pulmonary function in paediatric cystic fibrosis patients **15:15 - 15:30**
Gabriela Oates (Birmingham, United States)

New Pseudomonas chronicity score: evaluating association with clinical outcomes and comparing to Leeds criteria **15:30 - 15:45**
Margaret Rosenfeld (Seattle, United States)

Clinical effectiveness results from the first interim analysis of the VOCAL study: an observational study of ivacaftor in patients with cystic fibrosis and selected non-G551D gating mutations **15:45 - 16:00**
Arpeat Kaviya (London, United Kingdom)

Pregnancy outcome in women with cystic fibrosis and poor pulmonary function **16:00 - 16:15**
Quitterie Reynaud (Lyon, France)

Mortality outcomes related to multi-drug resistant organisms in cystic fibrosis lung transplant recipients: an International Society of Heart and Lung Transplantation (ISHLT) thoracic transplant Registry study **16:15 - 16:30**
Christian Benden (Zurich, Switzerland)

Scientific Programme

Symposium
17:00 - 18:30 Blue Hall

SS01, Standards of care: moving ahead

Pavel Drevinek (Prague, Czech Republic)
Martin Stern (Tübingen, Germany)

The implementation of best practice procedures around Europe **17:00 - 17:22**
Stefano Aliberti (Milan, Italy)

Evaluation of the quality of CF care from the patients' perspective **17:22 - 17:44**
Vincent Gulmans (Baarn, Netherlands)

Benchmarking in Scandinavia **17:44 - 18:06**
Tacjana Pressler (Copenhagen, Denmark)

Organisation of CF care: the Serbian experience **18:06 - 18:30**
Predrag Minic (Belgrade, Serbia)

Workshop
17:00 - 18:30 Hall 1

WS06, Assessing lung structure and function in cystic fibrosis

Immunology / Pulmonology / Inflammation

Harm Tiddens (Rotterdam, Netherlands)
Elpis Hatziagorou (Thessaloniki, Greece)

Monitoring cystic fibrosis lung disease in school-age children with computer tomography **17:00 - 17:15**
Marcus Svedberg (Gothenburg, Sweden)

Interest of sequential expiratory chest computed tomography in monitoring lung disease of children with cystic fibrosis **17:15 - 17:30**
Marie Mittaine (Toulouse, France)

A novel approach based on low field nuclear magnetic resonance to monitor lung functionality and inflammation in cystic fibrosis patients **17:30 - 17:45**
Michela Abrami (Trieste, Italy)

Lung ultrasound score and the relation with lung clearance index **17:45 - 18:00**
Ioana Mihaiela Ciuca (Timisoara, Romania)

A methodology to evaluate trapped gas using an open circuit multiple breath nitrogen washout (MBWN2) device **18:00 - 18:15**
Christopher Short (London, United Kingdom)

Effect of lumacaftor/ivacaftor on lung clearance index and exercise capacity among patients aged over 12 years with cystic fibrosis homozygous for F508del-CFTR **18:15 - 18:30**
Elpis Hatziagorou (Thessaloniki, Greece)

Scientific Programme

Workshop
17:00 - 18:30 Amphitheatre

WS07, Challenging cases in 21st century cystic fibrosis

Nursing / Psychosocial Issues / Complex Psychosocial / Nursing Case Studies

Kath MacDonald (Edinburgh, United Kingdom)
Pavla Hodkova (Prague, Czech Republic)

Moving into the 21st century with dietetic care - changing patient perceptions **17:00 - 17:15**
Emma Farrell (London, United Kingdom)

Emergent biopsychosocial challenges of novel drug development and clinical trial participation: stopping an experimental modulator drug in order to conceive **17:15 - 17:30**
Rebecca Dobra (London, United Kingdom)

The lonely patient: "I survived, now what?" **17:30 - 17:45**
Edwina Landau (Petah Tikva, Israel)

Bereavement and loss in a 14 year-old girl and the impact on cystic fibrosis **17:45 - 18:00**
Trudy Havermans (Leuven, Belgium)

Raising the medication intake in a kindergarten setting - a case report **18:00 - 18:15**
Angela Gabele (Zürich, Switzerland)

At a loss: the failings of multi-agency working? **18:15 - 18:30**
Holly Clisby (London, United Kingdom)

Workshop
17:00 - 18:30 Hall 2

WS08, Exercise: the fitter the better!

Physiotherapy

Helge Hebestreit (Würzburg, Germany)
Marta Kerstan (Biberstein, Switzerland)

The utility of oxygen uptake efficiency as a marker of aerobic fitness in children with cystic fibrosis **17:00 - 17:15**
Owen Tomlinson (Exeter, United Kingdom)

Acute effects of combined exercise and oscillatory positive expiratory pressure therapy on sputum properties and lung diffusing capacity in cystic fibrosis: a randomised, controlled, crossover trial **17:15 - 17:30**
Thomas Radtke (Zurich, Switzerland)

Combined ramp and supramaximal cardiopulmonary exercise testing for individuals with cystic fibrosis **17:30 - 17:45**
Zoe Saynor (Portsmouth, United Kingdom)

Feasibility of an incremental step test to assess aerobic fitness in adult cystic fibrosis **17:45 - 18:00**
Zelda Beverley (London, United Kingdom)

Scientific Programme

Balance, flexibility and agility - additional aspects of physical fitness and trainability in children and adolescents with cystic fibrosis **18:00 - 18:15**
Wolfgang Gruber (Essen, Germany)

Effects of home-based adapted physical activity in patients with cystic fibrosis: an interventional study **18:15 - 18:30**
Boubou Camara (Grenoble, France)

Workshop
17:00 - 18:30 Annex A

WS09, Pharmacology and genetic tools for cystic fibrosis basic research correction

Basic Science

Patrick T. Harrison (Cork, Ireland)
Rob Tarran (Chapel Hill, United States)

Development of a CFTR mRNA therapy capable of treating lung disease in all CFTR patients **17:00 - 17:18**
Thomas Mccauley (Cambridge, United States)

Developing scarless and permanent CFTR correction using CRISPRs **17:18 - 17:36**
Jim Hu (Toronto, Canada)

Development of effective method for F508del mutation correction using CRISPR/Cas9 **17:36 - 17:54**
Svetlana Smirnikhina (Moscow, Russian Federation)

Targeting αENaC with an epithelial RNAi trigger delivery platform for the treatment of cystic fibrosis **17:54 - 18:12**
Erik Bush (Madison, United States)

The ENaC regulatory peptide SPX-101 is stable in CF sputum and functional regardless of CFTR mutation **18:12 - 18:30**
David Scott (Durham, United States)

Workshop
17:00 - 18:30 Annex B

WS10, Screening around the globe: from foetus to newborn

Genetics / Screening / Diagnosis

Milan Jr Macek (Prague, Czech Republic)
Emmanuelle Girodon (Paris, France)

Isolated non-visualisation of foetal gallbladder should be considered for the prenatal diagnosis of cystic fibrosis **17:00 - 17:15**
Emmanuelle Girodon (Paris, France)

International approaches for delivery of positive newborn bloodspot screening results for cystic fibrosis **17:15 - 17:30**
Jane Chudleigh (London, United Kingdom)

Scientific Programme

Cystic fibrosis newborn screening in Austria: after 20 years changing the algorithm from IRT/IRT to IRT/PAP/IRT **17:30 - 17:45**

Sabine Renner (Vienna, Austria)

Evaluating cystic fibrosis newborn screening diagnostic performance in the United States **17:45 - 18:00**

Susanna A. McColley (Chicago, United States)

The Irish Comparative Outcome Study (ICOS): clinical outcomes at 3 years following introduction of newborn cystic fibrosis screening **18:00 - 18:15**

Patricia Fitzpatrick (Dublin, Ireland)

Seven years of nationwide cystic fibrosis newborn screening in the Czech Republic: analysis of the IRT/DNA/IRT scheme outcomes **18:15 - 18:30**

Milan Jr Macek (Prague, Czech Republic)

Scientific Programme

Friday, 08 June 2018

Symposium
08:30 - 10:00 Blue Hall

S13, Infection control and transmissibility in cystic fibrosis – what is clear and what is not?

Upon completion of this session participants should have:
- An overview of how CF infection control guidelines evolved and their importance in preventing cross-infection with CF pathogens
- Detailed knowledge of recent outbreaks of CF pathogens in Eastern Europe and lessons learnt from these outbreaks
- A focused understanding of disinfecting protocols as part of optimal infection prevention strategies in CF healthcare environments
- A detailed understanding of strategies to prevent aerosol transmission of CF pathogens

Tavs Qvist (Copenhagen, Denmark)
Michael Tunney (Belfast, United Kingdom)

How the CF infection control guidelines evolved **08:30 - 08:52**
Andrew Jones (Manchester, United Kingdom)

CF pathogen outbreaks in Eastern Europe **08:52 - 09:14**
Marina Yu Chernukha (Moscow, Russian Federation)

Disinfection protocols to prevent transmission of bugs **09:14 - 09:36**
Dieter Worlitzsch (Halle, Germany)

Strategies to prevent aerosol transmission in cystic fibrosis **09:36 - 10:00**
Timothy Kidd (Brisbane, Australia)

Symposium
08:30 - 10:00 Hall 1

S14, Early airway disease – how aggressive should we be?

Upon completion of this session participants should be able to:
- Understand the pathogenesis of early airway disease
- Learn about how to diagnose and monitor early airway disease
- Appreciate the complexities of treating early airway disease

Kris De Boeck (Leuven, Belgium)
Eitan Kerem (Jerusalem, Israel)

Pathogenesis of early airway disease **08:30 - 08:52**
Isabelle Sermet (Paris, France)

Identification and monitoring of early disease – how aggressive should we be? **08:52 - 09:14**
Eitan Kerem (Jerusalem, Israel)

Treatment of early disease – how aggressive should we be? **09:14 - 09:36**
Marijke Proesmans (Leuven, Belgium)

Scientific Programme

How will we manage CFTR modulators? **09:36 - 10:00**
Philippe Reix (Lyon, France)

Symposium
08:30 - 10:00 Amphitheatre

S15, Which bacteria require eradication in cystic fibrosis?

Upon completion of this session participants should be able to:
- Learn about the potential environmental sources of NTM infection
- Understand how whole genome sequencing can inform the epidemiology of NTM infection
- Get an overview of current treatment outcomes and discuss how we might approach NTM management in the future

Mieke Boon (Leuven, Belgium)
Predrag Minic (Belgrade, Serbia)

Pseudomonas aeruginosa **08:30 - 08:52**
Giovanni Taccetti (Florence, Italy)

Stenotrophomonas maltophilia **08:52 - 09:14**
Christine Roenne Hansen (Lund, Sweden)

Achromobacter **09:14 - 09:36**
Lieven Dupont (Leuven, Belgium)

MRSA **09:36 - 10:00**
Marianne S. Muhlebach (Chapel Hill, United States)

Symposium
08:30 - 10:00 Hall 2

S16, Whose patient is it anyway? Managing differences of opinion between MD teams and parents/patients

Upon completion of this session participants should be able to:
- Consider ethical, moral and medical decision-making processes within the CF Team
- Discuss the CF teams' relationships with parents and people with CF and the ways in which decision-making is negotiated in these relationships
- Be informed about developmental stages of young people with CF and consider how this might influence behaviours, treatment choices and decision-making

Janice Abbott (Preston, United Kingdom)
Jacquelien Noordhoek (Baarn, Netherlands)

Point: when is too little care too much harm? **08:30 - 08:52**
Mandy Bryon (London, United Kingdom)

Counterpoint: too little care or too little collaboration? **08:52 - 09:14**
Gregory Sawicki (Boston, United States)

Audience discussion (Pro/Con) **09:14 - 09:36**

Psychological support for young people who push the boundaries **09:36 - 10:00**
Katrien Van Gompel (Antwerp, Belgium)

Scientific Programme

Symposium
08:30 - 10:00 Annex A

S17, Body composition – aiming for the lean?

Upon completion of this session participants should be able to:
- Learn the importance of a good nutritional assessment in the management of cystic fibrosis
- Understand the multidisciplinarity of rebuilding lean body mass in cystic fibrosis

Sarah Collins (London, United Kingdom)
Dimitri Declercq (Ghent, Belgium)

We should routinely measure body composition in all patients – PRO **08:30 - 08:48**
Susannah King (Melbourne, Australia)

We should routinely measure body composition in all patients – CON **08:48 - 09:06**
Chris Smith (Brighton, United Kingdom)

Discussion **09:06 - 09:16**

The influence of CFTR-modulators on nutritional status **09:16 - 09:38**
Tanja Gonska (Toronto, Canada)

Lean body mass from the perspective of a physiologist **09:38 - 10:00**
Craig Williams (Exeter, United Kingdom)

Symposium
08:30 - 10:00 Annex B

S18, Novel analysis of CF Registry data

Upon completion of this session participants should be able to:
- Identify innovative uses of CF Registries
- Appraise the wealth of information contained in CF Registries
- Discover additional uses of epidemiological data sets

Ruth Keogh (London, United Kingdom)
Alexander Elbert (Bethesda, United States)

Understanding health inequalities with Registry data **08:30 - 08:52**
Daniela K. Schlüter (Lancaster, United Kingdom)

Can analysis of data using machine learning guide clinical decisions? **08:52 - 09:14**
Mihaela van der Schaar (London, United Kingdom)

Longitudinal, multi-country comparisons of CF Registry data **09:14 - 09:36**
Christopher Goss (Seattle, United States)

Longitudinal FEV_1% predicted using ECFSPR data **09:36 - 10:00**
Elpis Hatziagorou (Thessaloniki, Greece)

Scientific Programme

Symposium
10:30 - 12:00 Blue Hall

S19, Can we predict response to new therapies?

Upon completion of this session participants should be able to:
- Describe the different methods of epithelial cell culture
- Explain the characteristics of epithelial organoids
- Compare pros and cons of the different models available for *in vitro* CFTR drug testing

Tim Lee (Leeds, United Kingdom)
Jane Davies (London, United Kingdom)

Nasal epithelial cells for CFTR drug testing **10:30 - 10:52**
Iwona Pranke (Paris, France)

Stem cells as sources for CF disease modeling and drug discovery **10:52 - 11:14**
Massimo Conese (Foggia, Italy)

Intestinal vs. airway organoids **11:14 - 11:36**
Jeffrey Beekman (Utrecht, Netherlands)

New methodologies to implement clinical trials **11:36 - 12:00**
Kris De Boeck (Leuven, Belgium)

Symposium
10:30 - 12:00 Hall 1

S20, Upper airway disease management

Upon completion of this session participants should be able to:
- Understand the role of sinonasal infection in the acquisition and persistence of *P. aeruginosa* airway infection in CF
- Understand the medical and surgical treatment options for upper airway disease
- Learn about optimal management of the upper airway before and after lung transplantation

Jochen G. Mainz (Jena, Germany)
Tacjana Pressler (Copenhagen, Denmark)

The sinonasal role in acquisition and persistence of P. aeruginosa in CF airways **10:30 - 10:52**
Jochen G. Mainz (Jena, Germany)

Conservative treatment **10:52 - 11:14**
Assen Koitschev (Stuttgart, Germany)

Surgical treatment **11:14 - 11:36**
Ron Eliashar (Jerusalem, Israel)

Management before and after transplantation **11:36 - 12:00**
Letizia Corinna Morlacchi (Milan, Italy)

Scientific Programme

Symposium
10:30 - 12:00 Amphitheatre

S21, CF diagnosis - doing more good than harm

Upon completion of this session participants should be able to:
- Remember the weaknesses and strengths of different CF NBS protocols
- Interpret how different algorithms will influence the number of infants detected with CFSPID
- Assess the value of a CFSPID registry

Jürg Barben (St. Gallen, Switzerland)
Elke De Wachter (Brussels, Belgium)

Weaknesses and strengths of PAP in NBS **10:30 - 10:52**
Olaf Sommerburg (Heidelberg, Germany)

Weaknesses and strengths of DNA analysis in NBS **10:52 - 11:14**
Emmanuelle Girodon (Paris, France)

The challenges and opportunities of having a CFSPID registry **11:14 - 11:36**
Anne Munck (Paris, France)

Ambiguous clinical presentations – benefits and pitfalls of making a CF diagnosis **11:36 - 12:00**
Ana Kotnik Pirš (Ljubljana, Slovenia)

Symposium
10:30 - 12:00 Hall 2

S22, Ensuring standards of psychosocial care all across Europe: training, education, mentoring

Upon completion of this session participants should be able to:
- Recognise the East-West divide in application of The European Standards of CF Care
- Identify the differences in CF management across cultures
- Construct creative ways how teams can work together to promote best practice for social and mental wellbeing of people with CF and their families

Pavla Hodkova (Prague, Czech Republic)
Anna Elderton (Oxford, United Kingdom)

What does good mental health care look like - Western perspective **10:30 - 10:52**
Marieke Verkleij (Amsterdam, Netherlands)

What does good mental health care look like - Eastern perspective **10:52 - 11:14**
Urszula Borawska - Kowalczyk (Warsaw, Poland)

Training, education, mentoring **11:14 - 11:36**
Alistair Duff (Leeds, United Kingdom)

Social care expectations: East vs. West **11:36 - 12:00**
Suja Chandran (London, United Kingdom)

Scientific Programme

Symposium
10:30 - 12:00 Annex A

S23, Interactive case studies

Complicated Cystic Fibrosis-Related Diabetes: non-adherence or a new medication? **10:30 - 10:40**
Claire Edmondson (London, United Kingdom)

Renal involvement in an adult patient with cystic fibrosis **10:40 - 10:50**
Emma Luke (London, United Kingdom)

Novel approach to treat severe multi-drug-resistant P. aeruginosa lung disease **10:50 - 11:00**

Is this Cystic fibrosis? **11:00 - 11:10**
Marija Dimitrovska-Ivanova (Stip, Macedonia, the Republic of)

Symposium
10:30 - 12:00 Annex B

S24, The epithelial channelome and alternative strategies for rescue

This session focuses on alternative strategies for CF therapy. Speakers will focus on the potential therapeutic relevance of targeting novel CFTR regulators to improve F508del maturation and trafficking to the plasma membrane, as well as modulating non-CFTR channels and transporters to help restore chloride and bicarbonate secretion to improve airways hydration and pH

Michael Gray (Newcastle upon Tyne, United Kingdom)
Nicoletta Pedemonte (Genoa, Italy)

Novel CFTR regulators and their potential roles as drug targets **10:30 - 10:52**
Nicoletta Pedemonte (Genoa, Italy)

Manipulating acid-base transporters as a therapeutic approach for cystic fibrosis lung disease **10:52 - 11:14**
Vinciane Saint-Criq (Newcastle upon Tyne, United Kingdom)

CFTR and SLC26A9 interaction: prospects for therapy **11:14 - 11:36**
Marcus Mall (Berlin, Germany)

Rescue of the chloride permeability defect in CF by alternate ion channels **11:36 - 12:00**
Martin Gosling (Falmer, United Kingdom)

Satellite Symposium
12:30 - 14:00 Amphitheatre

Satellite Symposium

Please find the detailed program of the Satellite Symposia here.

Scientific Programme

Satellite Symposium
12:30 - 13:30 Annex B

Satellite Symposium

Please find the detailed program of the Satellite Symposia here.

Meet the Experts
12:45 - 13:45 ePoster Corners

Meet the Experts 4: Pregnancy

ePoster Corner A

Jennifer Taylor-Cousar (Denver, United States)
Malena Cohen-Cymberknoh (Jerusalem, Israel)

Meet the Experts
12:45 - 13:45 ePoster Corners

Meet the Experts 5: How to do a paper review?

ePoster Corner B

Scott Bell (Brisbane, Australia)
Patrick Flume (Charleston, United States)
Carlo Castellani (Verona, Italy)

Meet the Experts
12:45 - 13:45 ePoster Corners

Meet the Expert 6: Aging

ePoster Corner C

Nicholas Simmonds (London, United Kingdom)
Pierre-Régis Burgel (Paris, France)

Meetings and Courses
12:45 - 13:45 ECFS Tomorrow Lounge

Tomorrow Lounge Activity

Scientific Programme

ePoster Session
14:00 - 15:00 ePoster Corners

ePS5, Emerging insights from Registries

ePoster Corner B

Lutz Nährlich (Giessen, Germany)
Margaret Rosenfeld (Seattle, United States)

Introduction	**14:00 - 14:04**
Personalised time-updated predictions of short-term and long-term survival in cystic fibrosis using UK Registry data Ruth Keogh (London, United Kingdom)	**14:04 - 14:11**
Estimation of survival of cystic fibrosis patients in France by two different methods Virginie Scotet (Brest, France)	**14:11 - 14:18**
Stenotrophomonas maltophilia and Achromobacter xylosoxidans in cystic fibrosis: epidemiology and lung disease progression Linda Bouhlel (Nice, France)	**14:18 - 14:25**
The role of Pseudomonas infection in early growth trajectories in cystic fibrosis Amy Macdougall (London, United Kingdom)	**14:25 - 14:32**
Epidemiology and phenotype of cystic fibrosis with residual function mutations in Italy Donatello Salvatore (Potenza, Italy)	**14:32 - 14:39**
Demography and clinical outcomes in cystic fibrosis lung transplant recipients in Belgium Muriel Thomas (Brussels, Belgium)	**14:39 - 14:46**
Evaluating the impact of 2006 clinical practice guidelines for nutrition in children with cystic fibrosis in Australia Rasa Ruseckaite (Melbourne, Australia)	**14:46 - 14:53**
Quality improvement in CF: what can we learn from each other? A statistical analysis of UK Registry data and consultations with clinicians and patients Stephanie Macneill (Bristol, United Kingdom)	**14:53 - 15:00**

ePoster Session
14:00 - 15:00 ePoster Corners

ePS4, Microbiome interactions and updates on key pathogens

ePoster Corner A

Tavs Qvist (Copenhagen, Denmark)

Introduction	**14:00 - 14:04**
Microbial community composition in explanted cystic fibrosis lungs Christopher D. Spence (Belfast, United Kingdom)	**14:04 - 14:11**

Scientific Programme

Porphyromonas, a candidate biomarker for detection of Pseudomonas aeruginosa pulmonary infection in cystic fibrosis **14:11 - 14:18**
Geneviève Héry-Arnaud (Brest, France)

Clinical implications of the cystic fibrosis airway microbial metagenome **14:18 - 14:25**
Burkhard Tümmler (Hanover, Germany)

Characterising the intestinal virome in cystic fibrosis **14:25 - 14:32**
Michael Coffey (Sydney, Australia)

Determining the relationship between absolute quantification and relative abundance as determined by next generation sequencing **14:32 - 14:39**
Clodagh McGettigan (Belfast, United Kingdom)

Mutual antagonism: a complex coexistence of Aspergillus fumigatus and Pseudomonas aeruginosa in the cystic fibrosis airway **14:39 - 14:46**
Emma Reece (Dublin, Ireland)

Interactions of Pseudomonas aeruginosa with other bacterial species in an artificial sputum model **14:46 - 14:53**
Laura Wright (Liverpool, United Kingdom)

NTM infection in paediatrics: how do we approach these emerging pathogens? **14:53 - 15:00**
Gemma Saint (Liverpool, United Kingdom)

ePoster Session
14:00 - 15:00 ePoster Corners

ePS6, Mixing up physiotherapy

ePoster Corner C

Jamie Wood (Perth, Australia)

Introduction **14:00 - 14:04**

Shaking it up: a look at our centre experience with high frequency chest wall oscillation (HFCWO) **14:04 - 14:11**
Carwyn Bridges (Cardiff, United Kingdom)

Investigating the experience of adults with cystic fibrosis using long-term domiciliary non-invasive ventilation **14:11 - 14:18**
Jocelyn Choyce (Birmingham, United Kingdom)

Hypertonic saline use in our paediatric cystic fibrosis centre: using the UK cystic fibrosis Registry to reflect on practice **14:18 - 14:25**
Rachel O'Connor (London, United Kingdom)

Correlation between six-minutes-walk-test and cystic fibrosis disease severity **14:25 - 14:32**
Elad Ben-Meir (Ramat Gan, Israel)

A-STEP: a maximal, incremental, externally paced step test for adults with cystic fibrosis - safety and feasibility testing **14:32 - 14:39**
Lisa Wilson (Melbourne, Australia)

Scientific Programme

Influence of a supervised exercise program (CFmobil) on motor ability in adult cystic fibrosis patients **14:39 - 14:46**
Matthias Welsner (Essen, Germany)

Effects of physical retraining on the body composition of adult patients with cystic fibrosis **14:46 - 14:53**
Anne Prevotat (Lille, France)

The effects of Orkambi therapy on muscle strength, function, body composition and quality of life in cystic fibrosis patients homozygous for CFTR-F508del **14:53 - 15:00**
Clare M. Reilly (Dublin, Ireland)

ECFS Tomorrow Session
14:00 - 15:00 ECFS Tomorrow Lounge

ECFS Tomorrow Lounge Activity

Symposium
15:00 - 16:30 Blue Hall

SS02, The Early CF Years

Kevin Southern (Liverpool, United Kingdom)
Kris De Boeck (Leuven, Belgium)

Navigating the psychological pitfalls of the early CF years **15:00 - 15:22**
Trudy Havermans (Leuven, Belgium)

Achieving nutritional excellence in partnership with parents **15:22 - 15:44**

Aerosolized medicines for pre-school children with CF **15:44 - 16:06**
Felix Ratjen (Toronto, Canada)

Introducing new therapies to small children safely and promptly **16:06 - 16:30**

Workshop
15:00 - 16:30 Hall 1

WS11, Novel treatments for bacterial biofilms and bad bugs

Microbiology / Antibiotics

Barbara Kahl (Münster, Germany)

Alginate oligomers as novel therapies to treat life-threatening pseudomonal multidrug resistant bacterial infections **15:00 - 15:15**
Juliette Oakley (Cardiff, United Kingdom)

Hyperbaric oxygen treatment enhances the effect of tobramycin against biofilm-growing Pseudomonas aeruginosa **15:15 - 15:30**
Signe Agnete Møller (Copenhagen Ø, Denmark)

Scientific Programme

GVF27, HVA36 and IMY47: new human derived host defence peptides for alternative cystic fibrosis therapeutic intervention strategies **15:30 - 15:45**
Elio Pizzo (Naples, Italy)

The repurposed multiple sclerosis drug, glatiramer acetate, is an antibiotic resistance breaker in Pseudomonas aeruginosa strains from cystic fibrosis patients **15:45 - 16:00**
Ronan A. Murphy (London, United Kingdom)

Post-antibiotic effect of hypothiocyanite, lactoferrin and ALX-009 on clinical strains isolated from cystic fibrosis patients **16:00 - 16:15**
Victor Juarez Perez (Lyon, France)

The effect of 2-thiopyridine derivative 11026103, a novel antibacterial compound, on Burkholderia cenocepacia: transcriptomic response and resistance mechanisms **16:15 - 16:30**
Pavel Drevinek (Prague, Czech Republic)

Workshop
15:00 - 16:30 Amphitheatre

WS12, How cold electronics can help to provide warmth of care

Nursing / Psychosocial Issues

Daniel Peckham (Leeds, United Kingdom)
Joaquim Calvo-Lerma (Valencia, Spain)

Pioneering virtual reality technology for distraction therapy at the All Wales Adult CF Centre **15:00 - 15:15**
Anna Sayers (Penarth, United Kingdom)

Supporting cystic fibrosis care at University Hospital Limerick (UHL) through eHealth **15:15 - 15:30**
Niamh Murphy (Limerick, Ireland)

Telehealth monitoring for home intravenous antibiotics in cystic fibrosis **15:30 - 15:45**
Laura Blanch (Newcastle upon Tyne, United Kingdom)

Are goal-focused, motivational text messages effective at improving patients' belief in their own ability (self-efficacy) to complete inhaled therapies in adults with cystic fibrosis **15:45 - 16:00**
Kate Channon (London, United Kingdom)

A smartphone application for reporting symptoms in adults with cystic fibrosis: a randomised controlled trial **16:00 - 16:15**
Jamie Wood (Perth, Australia)

MyCyFAPP project: validation of the PEDsQL GI symptom scale to evaluate gastro-intestinal symptoms in children with cystic fibrosis **16:15 - 16:30**
Mieke Boon (Leuven, Belgium)

Scientific Programme

Workshop
15:00 - 16:30 Hall 2

WS13, Assessing the patient: it's not all about the chest

Physiotherapy

Andrew Jones (Manchester, United Kingdom)

Thoracic ultrasound as a useful tool to assess lung atelectasic areas and set the best physiotherapy **15:00 - 15:15**
Matteo Giuliari (Rovereto, Italy)

Musculoskeletal symptoms in adults with cystic fibrosis **15:15 - 15:30**
Elizabeth Clarke (Manchester, United Kingdom)

The impact of pain on physiotherapy care in cystic fibrosis **15:30 - 15:45**
Anna Meschi (Verona, Italy)

Experiences of non-invasive ventilation in a large adult cystic fibrosis centre and nationally **15:45 - 16:00**
Zelda Beverley (London, United Kingdom)

Assessment of the prevalence and severity of urinary and ano-rectal functional disorders and their impact on quality of life and sexuality in adult with cystic fibrosis in the French North-West Cystic Fibrosis Network **16:00 - 16:15**
Sophie Ramel (Roscoff, France)

Urinary incontinence in adult patients with cystic fibrosis: prevalence, impact on daily life and relationship with chronic cough **16:15 - 16:30**
Ernesto Crisafulli (Parma, Italy)

Workshop
15:00 - 16:30 Annex A

WS14, Clinical trials on lung inflammation, lung clearance and exercise

Clinical Trials / New Therapies

Isabelle Fajac (Paris, France)
Nicholas Simmonds (London, United Kingdom)

ROSCO-CF, a safety and efficacy clinical trial of (R)-roscovitine in cystic fibrosis patients **15:00 - 15:15**
Laurent Meijer (Roscoff, France)

Phase 3 randomised controlled study of the efficacy and safety of inhaled mannitol in adults with cystic fibrosis **15:15 - 15:30**
Elena Amelina (Moscow, Russian Federation)

Randomised, double-blind, controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with cystic fibrosis (PRESIS) **15:30 - 15:45**
Mirjam Stahl (Heidelberg, Germany)

Scientific Programme

Use of computational fluid dynamics to model aerosol deposition in the lungs of patients with cystic fibrosis **15:45 - 16:00**
Dearbhla Hull (Chichester, United Kingdom)

A randomised, controlled pilot study of sildenafil to treat exercise intolerance in moderate to severe cystic fibrosis **16:00 - 16:15**
Jennifer Taylor-Cousar (Denver, United States)

Demographics of patients in a phase 2 trial of acebilustat in patients with cystic fibrosis (EMPIRE CF) **16:15 - 16:30**
Stuart Elborn (London, United Kingdom)

Workshop
15:00 - 16:30 Annex B

WS15, The right pill for everyone - advancing towards personalised therapy

Basic Science

Marcus Mall (Berlin, Germany)

From the bench to bedside: expanding CFTR modulators to rare mutations by response assessment in patients-derived materials and cellular models **15:00 - 15:15**
Iris Silva (Lisboa, Portugal)

R334W CFTR, a severely compromised chloride conductance mutant, retains its bicarbonate conductance and responds to the corrector combination, C4+C18 **15:15 - 15:30**
Liudmila Cebotaru (Baltimore, United States)

Patterns of response to lumacaftor and ivacaftor in rectal organoids **15:30 - 15:45**
Paulien Peetermans (Leuven, Belgium)

First functional characterisation of the R751L CFTR mutation using an ex vivo primary airway epithelial cell culture model **15:45 - 16:00**
Iram Haq (Newcastle upon Tyne, United Kingdom)

Biomarkers to predict Orkambi efficacy: results of a prospective paediatric study **16:00 - 16:15**
Alexandra Masson (Paris, France)

A phase 3, open-label study of tezacaftor/ivacaftor (TEZ/IVA) therapy: interim analysis of pooled safety, and efficacy in patients heterozygous for F508del-CFTR and a residual function mutation **16:15 - 16:30**
Patrick Flume (Charleston, United States)

Scientific Programme

Workshop
17:00 - 18:30 Blue Hall

WS16, Towards new markers of disease severity

Immunology / Pulmonology / Inflammation

Barry Plant (Cork, Ireland)
Charles Haworth (Cambridge, United Kingdom)

Early multi-dimensional assessment of Parameters to assess Response to Intra-Venous Antibiotic Treatment for pulmonary Exacerbations: The PRIVATE Study **17:00 - 17:15**
Charlotte Addy (Belfast, United Kingdom)

Serum levels of PAD4 auto-antibodies correlate with airway obstruction in cystic fibrosis patients: novel systemic marker of lung disease? **17:15 - 17:30**
Ruchi Yadav (Athens, United States)

Investigation of inflammatory and fibrotic biomarkers in the sputum of cystic fibrosis patients **17:30 - 17:45**
Jan Christoph Thomassen (Cologne, Germany)

Plasma YKL-40 levels and chitotriosidase activity in cystic fibrosis patients **17:45 - 18:00**
Mina Hizal (Ankara, Turkey)

Examining serum TH2 inflammatory exacerbation biomarkers in cystic fibrosis **18:00 - 18:15**
Anna Siedlecki (VANCOUVER, Canada)

Human epididymis protein 4 (HE4) plasma levels inversely correlate with improved FEV1 in cystic fibrosis patients under ivacaftor therapy as a new sensitive treatment efficacy biomarker **18:15 - 18:30**
Béla Nagy Jr. (Debrecen, Hungary)

Workshop
17:00 - 18:30 Hall 1

WS17, Unraveling the complexities of CFTR mutations and their impacts

Genetics / Screening / Diagnosis

Margarida Amaral (Lisbon, Portugal)
Elke De Wachter (Brussels, Belgium)

The multi-faceted nature of CFTR exonic mutations: impact on their functional classification **17:00 - 17:15**
Caroline Raynal (Montpellier, France)

Using a highly parallel sequencing assay for CFTR genotyping in ethnically diverse European patients with cystic fibrosis **17:15 - 17:30**
Senne Cuyx (Leuven, Belgium)

Functional characterisation and CFTR2 disease liability assignment of 48 missense variants **17:30 - 17:45**
Karen Raraigh (Baltimore, United States)

Scientific Programme

How organoid assay results concur with the clinical phenotype in an unusual patient with S1251N/G542X **17:45 - 18:00**
Senne Cuyx (Leuven, Belgium)

Nasal potential difference measurement increases the diagnostic yield in patients with equivocal first-line cystic fibrosis investigations: the experience of a large national CFTR diagnostic service **18:00 - 18:15**
Nicholas Simmonds (London, United Kingdom)

Characteristics of the reproductive system in adult male patients with cystic fibrosis **18:15 - 18:30**
Svetlana Repina (Moscow, Russian Federation)

Workshop
17:00 - 18:30 Amphitheatre

WS18, Transplantation: waiting, caring, hoping

Open

Rachel Dunk (London, United Kingdom)
Amparo Solé (Valencia, Spain)

Waiting for lung transplant, manifold experiences: a literature review **17:00 - 17:15**
Ulrika Skogeland (Stockholm, Sweden)

The transition towards lung transplant for cystic fibrosis in the United Kingdom **17:15 - 17:30**
Natalile West (Baltimore, United States)

The introduction of a cystic fibrosis-specific advance care planning document **17:30 - 17:45**
Fiona Cathcart (London, United Kingdom)

Evaluation of transplantation information delivered to patients and their relatives by the professionals from cystic fibrosis centres and transplant centres and from transplanted peer-patients in France **17:45 - 18:00**
Valerie DAVID (Nantes, France)

Does lung transplantation have an effect on the improvement of psychological status in adult patients with cystic fibrosis? **18:00 - 18:15**
Ivana Lalic (Zagreb, Croatia)

Pregnancy after lung transplantation in cystic fibrosis patients **18:15 - 18:30**
Frederikke Rönsholt (Copenhagen, Denmark)

Scientific Programme

Workshop
17:00 - 18:30 Hall 2

WS19, Cystic Fibrosis-Related Diabetes: from diagnosis to pancreatic islet transplantation

Gastroenterology/Nutrition/Liver/Metabolic Complications

Isabelle Durieu (Lyon, France)
Helen White (Leeds, United Kingdom)

Glucose abnormalities in Canadian and French cystic fibrosis patients: a Glyc-one database analysis **17:00 - 17:15**
Quitterie Reynaud (Lyon, France)

The use of a questionnaire and continuous glucose monitoring to screen for hypoglycaemia in a cystic fibrosis clinic **17:15 - 17:30**
Natasha Armaghanian (Sydney, Australia)

Early screening and treatment of paediatric Cystic Fibrosis-Related Diabetes (CFRD) slows respiratory decline **17:30 - 17:45**
Charlotte Walker (London, United Kingdom)

Glucose and insulin area under the curve (AUC) can differentiate between cystic fibrosis patients that may benefit from early insulin treatment **17:45 - 18:00**
Liora Soesman (Jerusalem, Israel)

The main mechanism associated with glucose intolerance in older patients with cystic fibrosis is insulin resistance and not progressive insulin secretion deficit **18:00 - 18:15**
Valerie Boudreau (Montreal, Canada)

Feasibility and efficacy of combined lung and pancreatic islet transplantation in Cystic Fibrosis-Related Diabetes: a pilot study **18:15 - 18:30**
Laurence Kessler (Strasbourg, France)

Workshop
17:00 - 18:30 Annex A

WS20, Late Breaking science

Latebreaking Science

The importance of early diagnosis of Mycobacterium abscessus complex **17:00 - 17:23**
Tavs Qvist (Copenhagen, Denmark)

Evaluation of ELX-02 in Cystic Fibrosis Organoids with Non-Sense Mutations **17:23 - 17:38**
Pedro Huertas (Waltham, United States)

Spyryx **17:38 - 17:53**

BEAT-CF: An adaptive trial design for the treatment of respiratory tract exacerbations **17:53 - 18:03**

Panel discussion: Opportunities to run more effective clinical trials **18:03 - 18:13**
Stuart Elborn (London, United Kingdom)

Scientific Programme

Interactive Poster Discussions
17:00 - 18:30 Annex B

IPD2, What do we learn from CFTR modulator use in real life

Open

Jane Davies (London, United Kingdom)
Kris De Boeck (Leuven, Belgium)

Disease progression in patients with cystic fibrosis treated with ivacaftor: analyses of real-world data from the US and UK cystic fibrosis Registries
Nataliya Volkova (Boston, United States)

Real-world outcomes in patients with cystic fibrosis treated with ivacaftor: 2016 US and UK cystic fibrosis Registry analyses
Nataliya Volkova (Boston, United States)

The effects of 3-year ivacaftor use on lung function and intravenous days seen in UK cystic fibrosis Registry data
Simon J Newsome (London, United Kingdom)

Long-term effects of ivacaftor in patients with G551D mutation and mild lung disease
Helmut Ellemunter (Innsbruck, Austria)

Effects of ivacaftor in patients with cystic fibrosis and severe lung disease carrying CFTR mutations with residual function
Donatello Salvatore (Potenza, Italy)

Ivacaftor therapy in patients with severe baseline lung disease carrying a residual function mutation
Ruth Mitchell (Manchester, United Kingdom)

Retrospective observational study in cystic fibrosis patients homozygous for F508del treated with lumacaftor/ivacaftor in a compassionate use programme
Paola Iacotucci (Naples, Italy)

Dose modification of lumacaftor/ivacaftor and the immediate effects on lung function in cystic fibrosis patients with advanced lung disease and 12-month outcomes in this cohort
Natalia Popowicz (Perth, Australia)

Lumacaftor/ivacaftor improves 6 minute walk test distance, FEV1 and reduces exacerbations in severe cystic fibrosis lung disease
Theeba Thiruchelvam (New Lambton NSW, Australia)

Observational study of glucose tolerance abnormalities in patients with cystic fibrosis homozygous for Phe508del CFTR treated by lumacaftor-ivacaftor
Bastien Misgault (Strasbourg, France)

The potentially beneficial CNS-activity profile of ivacaftor and its metabolites
Elena Schneider (Melbourne, Australia)

Treatment with Orkambi™ in Phe508del homozygous cystic fibrosis patients is associated with improvement in cognition
John Wilson (Melbourne, Australia)

Treatment with ivacaftor in cystic fibrosis patients with the G551D mutation is associated with improvement in cognition
John Wilson (Melbourne, Australia)

Scientific Programme

Saturday, 09 June 2018

Symposium
09:00 - 10:30 Blue Hall

S25, Where are we with novel, single-drug approaches to CF therapy?

Upon completion of this session participants should be able to:
- Describe the molecular mechanisms that can be exploited to repair CFTR at the DNA and RNA levels
- Explain the concept of CFTR amplifier as an adjuvant therapeutic approach in cystic fibrosis
- Evaluate the importance of modifier genes on CFTR function

Dorota Sands (Warsaw, Poland)
George Z. Retsch-Bogart (Chapel Hill, United States)

Gene editing **09:00 - 09:22**
Patrick T. Harrison (Cork, Ireland)

mRNA repair **09:22 - 09:44**
Batsheva Kerem (Jerusalem, Israel)

Alternative chloride channels **09:44 - 10:06**
Karl Kunzelmann (Regensburg, Germany)

Targeting ENaC **10:06 - 10:30**
Rob Tarran (Chapel Hill, United States)

Symposium
09:00 - 10:30 Hall 1

S26, The new age of inflammation in cystic fibrosis

Upon completion of this session participants should be able to:
- Get an overview of inflammation in CF
- Understand the pros and cons of treating inflammation in CF
- Learn about possible future anti-inflammatory therapies in CF

Stuart Elborn (London, United Kingdom)
Scott Bell (Brisbane, Australia)

Systemic airway and gut inflammation in cystic fibrosis **09:00 - 09:22**
Burkhard Tümmler (Hanover, Germany)

Inflammation should be treated in cystic fibrosis - PRO **09:22 - 09:40**
Jerry A. Nick (Denver, United States)

Inflammation should be treated in cystic fibrosis - CON **09:40 - 09:58**
Scott Bell (Brisbane, Australia)

Discussion **09:58 - 10:08**

Pipeline of anti-inflammatory treatments **10:08 - 10:30**
Stuart Elborn (London, United Kingdom)

Scientific Programme

Symposium
09:00 - 10:30 Amphitheatre

S27, Co-evolution of CF pathogens – do they drive disease?

The purpose of this session is to:
- Give clinicians and basic scientists an understanding how multispecies interactions within airway microbial communities are critical for airway colonisation, responses to perturbations, and transitions between health and disease
- Discuss the role of multispecies social interactions in shaping *P. aeruginosa* pathogenicity in the CF lung with a particular focus on *Staphylococcus*, *Streptococcus* and *Aspergillus* species

Niels Høiby (Copenhagen, Denmark)
Cristina Cigana (Milan, Italy)

Microbiota interactions - understanding the networks **09:00 - 09:22**
Michael Tunney (Belfast, United Kingdom)

Pseudomonas-Staphyloccus interactions **09:22 - 09:44**
Christian van Delden (Geneva, Switzerland)

Aspergillus and Pseudomonas **09:44 - 10:06**
Craig Williams (Glasgow, United Kingdom)

Pseudomonas and Streptococcus **10:06 - 10:30**
Michael G. Surette (Calgary, Canada)

Symposium
09:00 - 10:30 Hall 2

S28, Important aspects of GI and nutrition in adult CF care

Upon completion of this session participants should be able to:
- Learn the gastro-intestinal aspects of an adult CF patient
- Learn the impact of nutrition in post transplantation care

Helen White (Leeds, United Kingdom)
Michael Wilschanski (Jerusalem, Israel)

Adult-specific gastro-intestinal complications – overview **09:00 - 09:22**
Chee Y. Ooi (Randwick, Australia)

Management of adult-specific gastro-intestinal complications **09:22 - 09:44**
Philippe Sogni (Paris, France)

Cystic fibrosis and disorders of the large intestine: colorectal cancer **09:44 - 10:06**
James Abraham (Minneapolis, United States)

Nutritional care after transplantation **10:06 - 10:30**
Francis Hollander (Utrecht, Netherlands)

Scientific Programme

Symposium
09:00 - 10:30 Annex A

S29, A new era: Registry-based clinical studies

Upon completion of this session participants should be able to:
- Appraise the value of Registries to design time and cost-effective clinical studies
- Identify how CF Registries can answer fundamental questions that might otherwise go unanswered
- Discover how contemporary comparison groups can be construed in CF Registries

Lutz Nährlich (Giessen, Germany)
Ed McKone (Dublin, Ireland)

Establishing European guidelines for Registry-based studies **09:00 - 09:22**
Lutz Nährlich (Giessen, Germany)

Real-world outcomes of Registry-based Pharmacovigilance **09:22 - 09:44**
Siobhan Carr (London, United Kingdom)

Registry studies: the feasibility of encounter based vs. yearly data collection **09:44 - 10:06**
Kevin Southern (Liverpool, United Kingdom)

Clinical trials and the Cystic Fibrosis Foundation Patient Registry **10:06 - 10:30**
Margaret Rosenfeld (Seattle, United States)

Symposium
09:00 - 10:30 Annex B

S30, Mucus: barrier properties and interactions

Upon completion of this session participants should be able to:
- Identify how mucins contribute to the barrier function of mucus and the challenges this poses for drug delivery
- Remember how CF pathogens can disrupt mucus properties
- Disuss how mucins inhibit biofilm formation and how mucus affects immune defence of the lung

Nicoletta Pedemonte (Genoa, Italy)
Dave Thornton (Manchester, United Kingdom)

The role of mucins and mucus clearance in the barrier properties of the airways **09:00 - 09:22**
Brian Button (Chapel Hill, United States)

The effect of mucin on Pseudomonas biofilm formation **09:22 - 09:44**
Katharina Ribbeck (Cambridge, United States)

The interplay between the mucus barrier and Aspergillus fumigatus **09:44 - 10:06**
Dave Thornton (Manchester, United Kingdom)

Study of mucus barrier formation using Muc5b-GFP mouse **10:06 - 10:30**
Jean-Luc Desseyn (Lille, France)

Scientific Programme

Closing Plenary
11:00 - 13:00 Blue Hall

Closing Plenary

Isabelle Fajac (Paris, France)
Kris De Boeck (Leuven, Belgium)
Predrag Minic (Belgrade, Serbia)

The future of precision medicine **11:00 - 11:30**
Kors Van der Ent (Utrecht, Netherlands)

tbc **11:30 - 12:00**

ECFS President Address **12:00 - 12:30**
Isabelle Fajac (Paris, France)

Closing Ceremony
12:30 - 13:00 Blue Hall

Closing Ceremony